Trial Profile
The Effect of LY2409021 on Blood Pressure and Pulse Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2018
Price :
$35
*
At a glance
- Drugs Adomeglivant (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Eli Lilly and Company
- 09 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 14 Sep 2014 Planned End Date changed from 1 Apr 2015 to 1 Jan 2015 as reported by ClinicalTrials.gov.